A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513009-30-00

Acronym

M24-885

Enrollment

572

Registered

2024-11-11

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Crohn’s Disease

Brief summary

Achievement of endoscopic remission at Week 12.

Detailed description

Clinical remission per Crohn's disease activity index (CDAI) at Week 12., Clinical remission per stool frequency (SF)/abdominal pain score (APS) at Week 12., Endoscopic response at Week 12.

Interventions

DRUGABBV-066 / Risankizumab

DRUGABBV-066

DRUGABBV-382

DRUGLutikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Achievement of endoscopic remission at Week 12.	—

Secondary

Measure	Time frame
Clinical remission per Crohn's disease activity index (CDAI) at Week 12., Clinical remission per stool frequency (SF)/abdominal pain score (APS) at Week 12., Endoscopic response at Week 12.	—

Countries

Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026